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An average of 3.35 years follow-up was used. IMSS population with hypertension was 
estimated using the national prevalence of 30.8% (20 years and older) reported by 
the National Health Survey of 2006, the proportion (70%) of the Mexican population 
over 20 years old reported by the National Population Council and the number of 
total IMSS afﬁ liates. a 5% discount rate was applied to costs. Results are presented 
in US dollars (exchange rate 13 MXN/dollar). RESULTS: Primary hypertension 
annual treatment cost per patient including related cardiovascular events was $556.56 
for patients treated with candesartan/HCT and $718.42 with losartan/HCT treatment. 
Theoretical savings yield by candesartan/HCT are $161.86 per patient. Calculated 
hypertension patients afﬁ liated to the IMSS was 10 million. Average annual savings 
given this population are $1.707 million for the institution with 1.8 million bed days, 
4.4 million physician visits and 5.3 million laboratory tests avoided. CONCLUSIONS: 
This analysis showed that the reduction of cardiovascular events with the use of 
candesartan/HCT for treating primary hypertension could save $1.707 million to the 
IMSS.
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OBJECTIVES: To evaluate the costs of ambrisentan within therapeutic health 
program in 2nd phase line treatment of adult patients with idiopathic, familiar or 
associated with connective tissue disease pulmonary hypertension of III NYHA stage. 
METHODS: The analysis compared two scenarios: existing and new. The existing 
one assumed application of bosentan, iloprost, treprostinil or sildenaﬁ l in patients with 
pulmonary hypertension of III NYHA stage in case of 1st line treatment with bosentan 
or sildenaﬁ l failure. The new one included also administration of ambrisentan. Popula-
tion’s abundance and market shares of drugs used in presented indication were esti-
mated on the basis of PHPOL Registry. Cost data were collected from public payer’s 
perspective (National Health Fund) in Poland and calculated in ﬁ ve years horizon. 
Ofﬁ cial ex factore price of Volibris® was provided by the producer. Cost analysis was 
performed under assumption that ambrisentan would be ﬁ nanced within the frame-
work of Catalogue of active substances used in therapeutic health programs. a range 
of variables was checked in a sensitivity analysis. RESULTS: Introduction of ambris-
entan to Catalogue of active substances used in therapeutic health programs and 
administration in 2nd line treatment of adult patients with idiopathic, familiar or 
associated with connective tissue disease pulmonary hypertension of III NYHA stage 
brought savings from public payer’s perspective amounted to: 178,782PLN 
(64,719PLN–342,497PLN) in ﬁ rst year, 385,054PLN (132,673PLN–769,277PLN) in 
second year, 614,006PLN (203,224PLN–1,266,372PLN) in third year, 646,137PLN 
(206,854PLN–1 366,336PLN) in fourth year and 674,573PLN (210,053PLN–
1,455,310PLN) in ﬁ fth following year. CONCLUSIONS: Treatment with ambrisentan 
leads to savings from public payer’s perspective and constitutes substantial therapeutic 
achievement (it is administered orally and only once a day unlike other drugs currently 
used in presented indication).
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OBJECTIVES: The purpose of this study was to perform comparative pharmacoeco-
nomic analysis of antithrombotic therapy with rivaroxaban (Xarelto®) and enoxapa-
rin (Clexane®) in the conditions of real clinical practice of total hip (THR) and knee 
(TKR) replacement. METHODS: The method of budget impact modeling was used. 
RESULTS: At equal duration of venous thromboembolism (VTE) prophylaxis at THR 
(35 days) rivaroxaban turned out to be more budget saving than enoxaparin by 2399 
RUB (62.71c), reducing the quantity of complications cases (pulmonary embolism, 
deep venous thrombosis, death) by 26 cases per one thousand patients. At various 
duration of prophylaxis at THR—rivaroxaban (35 days) and enoxaparin (14 days)—
rivaroxaban application has also demonstrated budget savings by 100 RUB(2.63c) 
thus reducing the quantity of complications by 74 cases per one thousand patients. 
The results of comparison of two weeks VTE prophylaxis after TKR have shown the 
most sizeable economy after rivaroxaban application by 7734 RUB(202.164c) and 
simultaneous complications decrease by 92 cases per one thousand patients. CON-
CLUSIONS: Rivaroxaban demonstrated budget savings compared to enoxaparin at 
all prophylaxis regiments at THR and TKR by reducing thrombosis complications.
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OBJECTIVES: AF is a big problem of the Russian Health Care System because cardio-
vascular diseases are the leaders in the structure of morbidity and mortality. Systemic 
statistics of AF and AF BI are unknown. Aim: To calculate the AF BI based on regional 
data and extrapolate the received data for Russia. METHODS: Evaluation of AF 
incidence and prevalence in dynamic (1995–2005) in the North-West region of Russia, 
calculation of direct and indirect costs and perspective modeling. RESULTS: As 
estimation—AF prevalence in Russia is 3.2/1000, incidence is 1,766/100,000, parox-
ysmal and persistent AF are increased from 0.6 to 1.8 and 0.25 to 0.6/1,000 accord-
ingly. Hypertension (73%), ischemic hart disease (65.2%), diabetes (9%) occurred in 
the ﬁ rst episode of AF. Hospitalization rate is increased by 66%, estimated rate is 
1.23 mln. pts./year, and it’s length is 6.9 days on the average, AF lethality is 1%. 
Disability rate is 40%, estimated amount of disability days is 3.3 mln/year. Calculated 
hospitalization cost for one year is 11.35 bln RUR (~c298 mln), cost for out-patients’ 
day-service—29.6 mln RUR (~c778 ths) and cost of out-patient treatment for all 
patients is no less than 32.5 bln RUR (c855 mln) including drugs cost—19.6 bln RUR 
(Euro). Estimated surgery cost is 260 mln RUR (c6.8 mln). Undirected adjusted cost 
is no less than 3 bln RUR (~c80 mln). CONCLUSIONS: AF BI in the Russian Federa-
tion leads to the biggest governmental, insurance and personal expenditures as com-
pared to the developed countries. Annual BI AF without deﬁ ciancial GDP per person 
is no less than c5.5 ths. Decreasing of AF BI can be particularly achieved in case of a 
better pharmaceutical control of AF aimed at saving budget charges due to the less 
hospitalization and surgeon rates.
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OBJECTIVES: The majority of cardiac device recipients are routinely followed. 
Implantable Cardioverter Deﬁ brillators (ICDs) devices must be systematically and 
continually monitored, with follow-up frequency adjusted for the patient’s underlying 
medical condition, device-related issues, and patient preferences. In México, in CMN-
IMSS La Raza, the current implant rate for ICD is 5 per million (equating to 30 new 
implants per year) and every year an average of 180 patients implanted with ICD are 
attending follow-up visits at La Raza hospital in Mexico. This simulation provides 
evidence to support the use of remote follow up and monitoring of ICDs via the 
CareLink Network as an alternative to follow-up consultations in attending an out-
patient clinic setting. METHODS: The simulation considers patients implanted with 
ICD (without CareLink) will on average require 4 in-clinic follow-up consultations 
per year whilst those with CareLink will only require 1 in-clinic follow-up consultation 
(4–6 weeks post implant) and 3 remote follow-up consultations. Reviewing patient 
data provided via the CareLink Network (remote monitoring consultation) requires 
an average 8.4 minutes of cardiac physiologist time compared to 25.8 minutes for an 
in–clinic follow-up consultation. RESULTS: For each patient per year the introduction 
of a remote monitor to support device follow-ups, lead to a reduction in cardiac 
physiologist time of 52.2 minutes equivalent to $17,970 MXP ($30,686 MXP without 
CareLink versus $12,716 MXP on CareLink). The cost of a cardiac physiologist time 
is $2630.00 MXP (per hour) equating to MXP 368.20 per remote follow-up versus 
$1130.90 MXP per in-clinic follow-up. CONCLUSIONS: The use of CareLink can 
potentially generate economic beneﬁ ts for the health professional, institution, health 
system and the patient.
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OBJECTIVES: To develop a model to assess the clinical and economic impact of a 
pocket-sized ultrasound (PSU) versus standard ultrasound for abdominal aortic aneu-
rysm (AAA) screening in Italy. METHODS: The model was developed from the 
perspective of the Servizio Sanitario Nazionale, the national health care system in Italy, 
during an 8-year time horizon for 65–74-year-old males who had smoked in their 
lifetime. Our model assumed 100% of eligible males could be screened with the PSU, 
as compared to 29% actually screened with standard ultrasound, and that screening 
with a PSU would incur no additional cost. Model inputs were derived from major 
clinical trials (4-year rates of mortality, aortic rupture, and elective and emergency 
surgeries) and DRG reimbursement rates (costs). Model outputs of number of deaths, 
ruptures and costs (2010 euros) were calculated. One-way sensitivity analyses were 
conducted. RESULTS: A PSU strategy yielded a 33.8% (0.32% vs. 0.48%) and 46.6% 
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(0.42% vs. 0.79%) reduction in rates of AAA-related mortality and rupture, respec-
tively, as compared to the standard ultrasound strategy. During an 8-year follow-up 
period, the higher cost of elective surgeries by the PSU strategy was partially offset by 
lower rates and costs of emergency surgeries compared to the standard ultrasound 
strategy. The higher screening rate with the PSU strategy resulted in a cost savings of 
c17 per screened eligible male over 8 years (annualized c2/year). Sensitivity analyses 
demonstrated reductions in deaths and aortic ruptures ranging from 17% to 50% and 
2% to 73%, respectively, at a maximum cost-savings of c7 to c50, and only one 
instance of an incremental cost of c3 per eligible patient over 8 years. CONCLU-
SIONS: Use of a PSU device to screen for AAA may reduce deaths, aortic ruptures, 
and surgery costs with a savings of c2/year per screened eligible male.
PCV40
CLINICAL AND ECONOMIC IMPACT OF USE OF A POCKET-SIZED 
ULTRASOUND DEVICE FOR HEART FAILURE HOSPITALIZATIONS IN 
ITALY
Patel PA1, Shah M2, D’Souza AO3, Min JK4
1GE Healthcare, Barrington, IL, USA; 2Xcenda, Palm Harbor, FL, USA; 3Xcenda, Cincinnati, 
OH, USA; 4Weill Medical College of Cornell University, New York, NY, USA
OBJECTIVES: Patients hospitalized for Heart Failure (HF) continue to have high 
re-admission and mortality rates in the 30 days following discharge. Cardiac param-
eters such as left ventricular function (LVF) and inferior vena cava (IVC) size are 
predictors of mortality and readmission, and are presently assessed by 2-dimensional 
echocardiography (2DE). Pocket-sized ultrasound (PSU) devices for LVF and IVC 
assessment offer potential advantages of lower cost, increased availability, and porta-
bility as compared to 2DE. The study objective was to develop a model to assess the 
clinical and economic impact of PSU versus 2DE for HF hospitalizations in Italy. 
METHODS: The model was developed from an Italian hospital perspective, and 
timeframe was during HF hospitalization to 30 days post-discharge. The clinical 
scenario evaluated the impact of LVF assessment on mortality, while the economic 
scenario incorporated the impact of IVC size on costs (2010 Euros). Our model 
assumed 100% of PSU patients would undergo evaluation, as compared to only 68% 
who currently undergo 2DE. We assumed abnormalities identiﬁ ed by PSU would 
require subsequent 2DE evaluation while lack of abnormalities would not require 
2DE. Model outputs of number of deaths, readmissions, and costs were calculated 
using a sample of 186,000 HF hospitalizations. One-way sensitivity analyses were 
conducted to evaluate the robustness of model outcomes. RESULTS: A PSU strategy 
yielded a 19.1% (7.2% vs. 8.1%) reduction in the 30-day mortality rate, as compared 
to the 2DE strategy, and a 33.4% (26.0% vs. 39.1%) reduction in 30-day readmis-
sions leading to a cost savings of c55 million (c297/ HF admission). Models were 
robust to changes in model inputs with reduction in deaths from 2–37%, and cost 
savings from c63–315 per HF admission. CONCLUSIONS: Use of a PSU device to 
visualize key cardiac parameters for HF hospitalizations in Italy may afford reduction 
in deaths and cost-savings.
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OBJECTIVES: To assess and compare direct in-hospital costs in patients hospitalized 
with acute coronary syndromes (ACS; unstable angina or myocardial infarction), acute 
heart failure (AHF) and acute coronary syndromes complicated by heart failure (ACS 
with AHF) from health care payer perspective. METHODS: Patients hospitalized from 
2005 to 2008 were classiﬁ ed in registry of Faculty Hospital Brno according to the 
clinical characteristics. Direct in-hospital costs (ﬂ at rate of admission and stay; medica-
tion and procedures) were evaluated in total 965 ACS (73% male; 64.7 years; 54% 
STEMI), 962 AHF (56% male; 70.8 years) and 808 AHF with ACS (62% male; 71.2 
years; 61% STEMI) patients. The severity of disease was qualiﬁ ed as need of intensive 
care (ICU days); the predictors of high cost were identiﬁ ed in all groups. (1c = 26CZK). 
RESULTS: Mean in-hospital cost was 101658CZK/3910c in ACS pts (length-of-stay 
5.6 days; 81% pts 2.3 ICU days; 0.3% died), 70201CZK/2700c in AHF pts (length-
of-stay 9 days; 48 % pts 4 ICU days; 11.4 % died) and 122340CZK/4705c in ACS 
with AHF (length-of-stay 7.2 days; 92% pts 3.5 ICU days; 19.2% died). Percutaneous 
coronary intervention with stenting (PCI) formed more than 80% of total cost in ACS 
patients (performed in 78% pts.; 91% STEMI; 62% non-STEMI) and almost 60% 
costs in ACS with AHF pts (performed in 66% pts; 84% STEMI; 39% non-STEMI); 
antiarrhythmic interventions (incl. ICD, CRT BiV or PM device) made almost 50% 
cost in AHF although carried out in 8.6% pts. CONCLUSIONS: According to in-
hospital costs patients with acute coronary syndromes complicated by heart failure 
were the most costly with maximum need of intensive care. Since 26.7% pts were 
transferred to other health care institution (e.g. 9% cardiosurgery) we expect the most 
signiﬁ cant increase of total amount of direct in-hospital costs in comparison with ACS 
(16.9% pts transferred) or AHF (11.5% pts transferred).
PCV42
HOSPITALIZATION COSTS IN SOUTH KOREA FOR PATIENTS 
WITHOUT IDENTIFIED RISK FACTORS FOR BLEEDING WHO HAVE 
ACUTE CORONARY SYNDROMES WITH PLANNED PERCUTANEOUS 
CORONARY INTERVENTION TREATED WITH PRASUGREL VS. 
CLOPIDOGREL IN THE TRITON-TIMI 38 TRIAL
Mahoney E1, Wang K1, Yang BM2, Kim BRM2, Lee HY3, Chae IH4, Kang SY5
1Mid America Heart Institute of Saint Luke’s Hospital, Kansas City, MO, USA; 2Seoul 
National University, Seoul, South Korea; 3School of Public Health Seoul National University, 
Seoul, South Korea; 4Seoul National University, Seongnam, South Korea; 5Eli Lilly & 
Company, Korea, Gangna-gu, South Korea
OBJECTIVES: The TRITON-TIMI 38 Trial demonstrated that in patients with acute 
coronary syndromes (ACS) undergoing planned percutaneous coronary intervention 
(PCI), prasugrel compared to clopidogrel signiﬁ cantly reduced the rate of ischemic 
events over up to 15 months of follow-up, though there was an increased risk of major 
bleeding. Three risk factors for bleeding identiﬁ ed in the trial were a prior history of 
stroke/TIA, age ≥75 years, and body weight <60 kg. Patient-level data from TRITON 
was used to compare hospitalization costs in South Korea for patients without these 
risk factors for bleeding, who were randomized to prasugrel vs. clopidogrel. 
METHODS: Details regarding hospitalizations for all patients from 8 high enrolling 
countries (US, Australia, Canada, Germany, Italy, Spain, UK, France; n = 3373 pra-
sugrel, 3332 clopidogrel) were collected prospectively. The US diagnosis-related group 
codes were assigned to all hospitalizations, to which 2009 South Korean unit costs 
were applied. Estimates of incremental costs associated with PCI-associated peripro-
cedural MIs and PCI- and CABG-associated bleeding events were added separately, 
based on published U.S. data. RESULTS: Prasugrel was associated with a 17,723 
KRW per patient increase in costs due to bleeding, and an 8,377 KRW decrease in 
costs due to reduced periprocedural MI, during the index hospitalization. Per-patient 
costs from hospitalization for MI (not involving revascularization) during the follow-
up period were 291,022 KRW lower with prasugrel compared to clopidogrel, and 
costs associated with revascularization hospitalizations during follow-up were 
505,032 KRW lower. Costs from follow-up bleeding events were 52,082 KRW higher 
for prasugrel, while aggregate hospitalization costs were 293,656 KRW lower. CON-
CLUSIONS: For ACS patients with planned PCI, the lower ischemic event rate with 
prasugrel yields a reduction in overall hospitalization costs, despite increased costs 
from bleeding. These results have implications for the cost-effectiveness of alternative 
antiplatelet strategies for ACS patients undergoing PCI in South Korea.
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OBJECTIVES: To compare cardiovascular disease (CVD) associated costs between 
patients continuing statin (simvastatin 20 mg/day or equivalent) monotherapy (SM) 
or receiving adjunct therapy with niacin extended-release (NER) for comprehensive 
lipid management. METHODS: Secondary risk patients age ≥30 continuing SM or 
augmenting statin therapy with NER between January 1, 2005-November 30, 2008 
(index date) with ≥1 pre-index lipid panel (LDL-C < 100 mg/dL & HDL-C < 50 or 
<55 mg/dL for men & women, respectively) and no hepatic dysfunction were included. 
SM patients were matched 3:1 to NER patients based on prior exposure to statin. The 
primary outcome was total (medical and pharmacy) annual CVD-related costs. 
Medical and pharmacy costs consisted of inpatient, emergency room, and outpatient 
expenditures associated with CVD and pharmacy charges for anti-hyperlipidemic 
therapy. Outcome comparison between SM and NER and was conducted via general-
ized linear models via gamma distribution and log-link function. Multivariate analyses 
controlled for age, gender, geography, co-morbidities, and baseline lipids. RESULTS: 
A total of 728 patients were identiﬁ ed; 546 SM patients were matched to 182 NER 
patients. Compared to SM, there was no difference in baseline LDL-C (P = 0.13) or 
Deyo-Charlson co-morbidity Index scores (P = 0.77). Baseline HDL-C (35 ± 6 vs. 42 
± 7; P < 0.0001) was lower and TG (190 ± 98 vs. 153 ± 76; P < 0.0001) was higher 
among NER patients. While annual CVD-related pharmacy expenditure was higher 
for NER [mean (95% CI), $2261 ($1991–$2587) vs. $1276 ($1186–$1373)], adjusted 
and unadjusted medical costs were 69% (P = 0.0002) lower for NER ($542 ($378–
$799) vs. $1718 ($1373–$2149); P < 0.0001) vs. SM. Offsets in medical and pharmacy 
costs resulted in total annual CVD-related costs between NER and SM (($2796 
($2331–$3353) vs. $2988 ($2960–$3318); P = 0.5346). CONCLUSIONS: Therapy 
augmentation with NER for comprehensive lipid management was associated with 
reduced annual CVD-related medical expenditure leading to total annual CVD-related 
costs compared to statin monotherapy.
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OBJECTIVES: Compare the risk of subsequent coronary event (SCE), cerebrovascular 
event, and associated medical costs between patients maintaining statin monotherapy 
(SM) or augmenting statin with fenoﬁ brate (FF) after an acute coronary event (ACE). 
